53 results
Page 2 of 3
8-K
EX-1.1
ha1c8
25 Jun 21
Entry into a Material Definitive Agreement
5:22pm
8-K
EX-10.1
1pq9qg8yfx9a x0mmha
21 Jun 21
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-99.1
upekk27g6 nw
21 Jun 21
Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
8:35am
8-K
EX-99.1
yjbev6q
25 May 21
Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
9:01am
8-K
EX-99.1
e7zvahko1h9ewukozvv2
30 Mar 21
Moleculin Receives FDA Approval of Fast Track
7:30am
8-K
EX-99.1
bujkw 5ys
8 Feb 21
Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases
7:29am
8-K
EX-1.1
rcoi raq5
4 Feb 21
Moleculin Announces Proposed Underwritten Public Offering
4:07pm
8-K
EX-99.1
f86njh nbjdj4y
1 Feb 21
Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial
7:29am
S-8
EX-4.4
p7n0 uf82vt
21 Aug 20
Registration of securities for employees
4:31pm
8-K
EX-1.1
81rgg vwsi2o0vo
17 Jul 20
Entry into a Material Definitive Agreement
5:19pm
424B5
hsve 5ar0w1xh
17 Jul 20
Prospectus supplement for primary offering
5:16pm
8-K
EX-1.1
8k15q 9fdzvyajj
6 Feb 20
Entry into a Material Definitive Agreement
9:06am
8-K
EX-1.1
grfy9uruen3 2gx
24 Jul 19
Entry into a Material Definitive Agreement
7:30am
8-K
EX-1.1
5mfqzaua
23 Apr 19
Moleculin Announces $15.0 Million Registered Direct Offering
9:34pm
8-K
EX-1.1
e87xz5ayf6usbifnigmm
28 Mar 19
Moleculin Announces Proposed Underwritten Public Offering
6:18am
424B3
rd59o
29 Oct 18
Prospectus supplement
5:01pm